Transplantation and Cellular Therapy Journal

This single-center study finds pulmonary impairment occurs in more than half of myelofibrosis patients after #HCT, with bronchiolitis obliterans among the most common causes, highlighting the need for closer post-transplant lung monitoring. Read more: astctjournal.org/article/S2666-…

This real-world study finds that combining #CART therapy with autologous transplantation improves complete remission and long-term survival in relapsed or refractory diffuse large B-cell lymphoma compared with CAR-T alone. Read more: ow.ly/W8br50YuN8T

This review examines the current state of #CART therapy in pediatric B-ALL, assess current and emerging integration of CAR T-cells into treatment algorithms and discuss emerging strategies to overcome existing challenges. Read: astctjournal.org/article/S2666-…

Federal investigators abstracts and late-breaking abstracts from the 2026 Tandem Meetings are now available to view in a special supplement: #closeFullCover" target="_blank" rel="nofollow noopener">astctjournal.org/issue/S2666-63… #Tandem26

A Phase II trial is testing whether uproleselan can reduce the significant GI toxicity caused by high‑dose melphalan in autologous #HCT for multiple myeloma. Early findings support its potential, with more research needed to refine dosing and impact. ow.ly/cakz50YrRot

Nutritional care is essential across the #HCT journey. @ASTCT and expert dietitians outline best‑practice FAQs—from pre‑HCT assessment to early and long‑term interventions—while highlighting research needs to improve outcomes for adult HCT patients. ow.ly/pQqY50YrRiG

As a part of Women's History Month, we're highlighting recent articles published by our female associate editors and editorial board members. See the full collection here: astctjournal.org/womens-history…

The March issue of 'Transplantation and Cellular Therapy,' is now available online: astctjournal.org/current @ELShematology

The January issue of 'Transplantation and Cellular Therapy,' is now available online: astctjournal.org/current @ELShematology

We reflect on 30 years of progress in hematopoietic cell transplantation and cellular therapy. This editorial traces the evolution of the ASTCT journal from BBMT to Transplantation and Cellular Therapy and looks ahead to what’s next. ow.ly/Nu9w50XLepg

A CIBMTR analysis shows anti-CD19 #CART therapy offers promising outcomes in relapsed Richter transformation, with a 71% overall response rate and 57% complete response rate. Read the full article: astctjournal.org/article/S2666-…

New report from the second Reimagining Caregiving Together workshop outlines a research agenda to improve caregiver support in #HCT, with priorities including awareness, patient-centered models, policy change and community engagement. astctjournal.org/article/S2666-…

This study’s new phase II trial shows haploidentical #HSCT with umbilical cord blood coinfusion leads to rapid engraftment, low #GVHD and high 2-year survival. Read the full study: astctjournal.org/article/S2666-…

New article proposes DIPSS with Splenomegaly (DIP3S) as a better risk stratification tool for myelofibrosis patients treated with pretransplant JAK inhibitors, as DIPSS alone did not predict transplant outcomes in this setting. astctjournal.org/article/S2666-…

New article shows real-time PROMs are feasible and well-accepted in cell therapy care. Previsit tools improved shared decision-making and revealed key symptoms trends. Read the full article: astctjournal.org/article/S2666-…

Read this single-center study (2021–2024) to learn how anti-CD38 mAb therapy impacts stem cell mobilization in newly diagnosed multiple myeloma — showing lower yields, higher plerixafor use and added costs. Full study: astctjournal.org/article/S2666-…

This review highlights the importance of assessing social determinants of health in transplant and #CART recipients, recommending pre-TCT screening and calling for validated tools to better predict and improve outcomes. Full review: astctjournal.org/article/S2666-…

This study compares adjuvant umbilical cord blood vs. mesenchymal stem cells in #alloHSCT for aplastic anemia. Mesenchymal stem cells reduced chronic #GVHD and improved survival, while well-matched UCB also showed strong outcomes. astctjournal.org/article/S2666-…

Explore the full collection of @ASTCT clinical practice guidelines published in “Transplantation and Cellular Therapy,” covering infection prevention, GVHD management, survivorship and more. Start here: astctjournal.org/astct-publicat…

A study suggests that fludarabine exposure during lymphodepletion is linked to higher rates of CRS, ICANS, cytopenias and infections after ide-cel in relapsed/refractory multiple myeloma. Read the full study: astctjournal.org/article/S2666-…